By the Top Tier Newswire AI Desk · August 17, 2026 at 9:31 AM ET · reviewed against 8 wire stories
EYEPOINT INC (EYPT) is drawing unusual attention today. Our newswire has captured 8 stories on EYPT across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why EYPT stock is moving today
EYPT stock is moving sharply lower today, down 69% to $4.07 in pre-market trading, following the release of topline results from its Phase 3 LUGANO trial for Duravyu. The primary driver of the decline is the announcement that the primary endpoint of best-corrected visual acuity (BCVA) was not met in the full dataset. The drug was also found to be non-inferior to aflibercept only in an ad hoc analysis that excluded a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD.
What Happened
EyePoint Inc. disclosed the results of its LUGANO trial, the first of two pivotal Phase 3 studies for Duravyu in treating wet age-related macular degeneration (AMD). The trial showed that Duravyu reduced treatment burden by 42% and demonstrated strong durability and favorable safety. However, the primary BCVA endpoint was not met in the full dataset. In an ad hoc analysis excluding a 4% asymmetric cohort, the drug was non-inferior to aflibercept, with a nominal p-value of 0.0096. The 8-K filing on August 17 confirmed the trial results and outlined the financial details. The stock opened with a 56.3% gap down from the prior close of $14.75 and has since traded as low as $3.50.
What The Data Shows
The stock’s intraday session has been highly volatile, with a low of $3.50 and a high of $6.90, and volume has surged to 5.2 million shares, or 4.3 times the 3-month average. The stock has moved from $12.25 to $14.75 over the last 8 sessions before today’s drop. The 52-week tape showed 23 fresh 52-week highs on August 17, highlighting recent strength before the trial results. A single unusual put option print of $391K has also been recorded in the last 36 hours. The CEO of EyePoint has not made any recent transactions, and the only insider trade in the last 90 days was a $73K sale by the Chief Medical Officer on June 30.
What To Watch
EyePoint has no scheduled earnings date in the near term. Investors should monitor coverage breadth and potential follow-up analyses of the LUGANO trial results, as well as any further corporate actions or regulatory updates.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
EYPT · Aug 17 session (5-min) · -67.46% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 8 stories · 43/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
26d agoStocktwits NewsBEARISH 28Product/PR
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.
27d agoThe FlyBEARISH 28Earnings
Morning Movers: EyePoint plummets following LUGANO trial results
27d agoSEC 8-KNEUTRAL 50General
EyePoint, Inc. (EYPT) files 8-K
Filed: 2026-08-17 AccNo: 0001193125-26-353308 Size: 15 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
27d agoThe FlyBEARISH 22Product/PR
EyePoint down 69% at $4.52 as Duravyu phase 3 study endpoint was not met
27d agoReutersBEARISH 19Product/PR
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
27d agoThe FlyBULLISH 59Product/PR
EyePoint announces topline results from LUGANO trial
27d agoMarketChameleonBULLISH 73Product/PR
DURAVYU Reduces Wet AMD Treatment Burden by 42%: Phase 3 LUGANO Results Highlight Supplement-Free Durability
August 17, 2026
EyePoint's topline results from the LUGANO Phase 3 trial show DURAVYU offers a 42% reduction in injection burden for wet AMD patients, with strong durability and favorable safety. Despite a confounding asymmetric cohort impacting the primary endpoint, key secondary outcomes—including supplement-free rates and anatomical stability—reinforce DURAVYU’s transformative potential. Further pivotal data is expected in late 2026, with possible FDA application in 2027.
27d agoBusiness InsiderBULLISH 67Product/PR
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD;...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →